Author(s)
Taushif Khan
Published 6 Projects
COVID-19 Immunology Autoimmunity Microbiology Bioinformatics
Farhan S Cyprian
Qatar Univerisity
Published 1 Project
COVID-19 Autoimmunity Infectious Diseases Icu And Coronavirus.
Laith J Abu-Raddad
Published 1 Project
COVID-19 Autoimmunity Infectious Diseases Icu And Coronavirus.
Abdullatif Al-Khal
Published 1 Project
COVID-19 Autoimmunity Infectious Diseases Icu And Coronavirus.
Asmaa A. Al Thani
Published 1 Project
COVID-19 Autoimmunity Infectious Diseases Icu And Coronavirus.
Content
Video Abstract (AI generated) (01:48) Paper PreprintThe heterogeneity of COVID-19 lies within its diverse symptoms and severity, ranging from mild to lethal. Acute respiratory distress syndrome (ARDS) has been shown to be the leading cause of mortality in COVID-19 patients, characterized by a hyper cytokine storm. Autoimmunity is proposed to occur as a result of COVID-19, given the high similarity of the immune responses observed in COVID-19 and autoimmune diseases. Here, we investigate the level of autoimmune antibodies in COVID-19 patients with different severities. Initial screening for antinuclear antibodies (ANA) IgG revealed that 1.6% (2/126) and 4% (5/126) of ICU COVID-19 cases developed strong and moderate ANA levels, respectively. However, all the non-ICU cases (n=273) were ANA negative. The high ANA level was confirmed by immunofluorescence (IFA) and large-scale autoantibody screening by phage immunoprecipitation-sequencing (PhIP-Seq). Indeed, the majority of the samples showed "speckled" ANA pattern by microscopy, and we demonstrate that samples of ICU patients with strong and moderate ANA levels contain autoantibody specificities that predominantly targeted proteins involved in intracellular signal transduction, metabolism, apoptotic processes, and cell death; further denoting reactivity to nuclear and cytoplasmic antigens. In conclusion, our results further support the notion of routine screening for autoimmune responses in COVID-19 patients, which might help improve disease prognosis and patient management. Further, results provide compelling evidence that ANA-positive individuals should be excluded from being donors for convalescent plasma therapy in the context of Covid-19.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 3 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 3 years ago
Jignesh H. Parmar
0 views • 2 years ago
Winston A. Haynes
0 views • 2 years ago
Noam Mazor
0 views • 2 years ago
Global Immunotalks
182 views • 3 years ago
Cem Yuksel
345 views • 2 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Taushif Khan. (2021, Oct 25).Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients[Video]. Scitok. https://scitok.com/project/p/f0143c50
D. Fakhro Aisha. "Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients" Scitok, uploaded by Khan Taushif, 25 Oct, 2021, https://scitok.com/project/pf0143c50
Taushif Khan. "Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients" Scitok. (Oct 25, 2021). https://scitok.com/project/p/f0143c50
Taushif Khan (Oct 25, 2021). Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients Scitok. https://scitok.com/project/p/f0143c50
Taushif Khan. Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients[video]. 2021 Oct 25. https://scitok.com/project/p/f0143c50
@online{al2006link, title={ Detection of autoimmune antibodies in severe but not in moderate or asymptomatic COVID-19 patients }, author={ Khan, Taushif }, organization={Scitok}, month={ Oct }, day={ 25 }, year={ 2021 }, url = {https://scitok.com/project/p/f0143c50}, }